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Abstract Purpose: Systemic
levels of soluble urokinase-type
plasminogen activator receptor
(suPAR) positively correlate with the
activation level of the immune sys-
tem. We reviewed the usefulness of
systemic levels of suPAR in the care
of critically ill patients with sepsis,
SIRS, and bacteremia, focusing on its
diagnostic and prognostic value.
Methods: A PubMed search on
suPAR was conducted, including
manual cross-referencing. The list of
papers was narrowed to original
studies of critically ill patients. Ten
papers on original studies of critically
ill patients were identified that report
on suPAR in sepsis, SIRS, or bacter-
emia. Results: Systematic levels of
suPAR have little diagnostic value in
critically ill patients with sepsis,
SIRS, or bacteremia. Systemic levels
of suPAR, however, have superior
prognostic power over other com-
monly used biological markers in
these patients. Mortality prediction by
other biological markers or severity-
of-disease classification system
scores improves when combining
them with suPAR. Systemic levels of
suPAR correlate positively with
markers of organ dysfunction and
severity-of-disease classification sys-
tem scores. Finally, systemic levels of
suPAR remain elevated for prolonged
periods after admission and only tend
to decline after several weeks. Nota-
bly, the type of assay used to measure
suPAR as well as the age of the
patients and underlying disease affect
systemic levels of suPAR. Conclu-
sions: The diagnostic value of
suPAR is low in patients with sepsis.
Systemic levels of suPAR have
prognostic value, and may add to
prognostication of patients with sep-
sis or SIRS complementing severity-
of-disease classification systems and
other biological markers.
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Introduction
Systemic levels of soluble urokinase plasminogen acti-
vator receptor (suPAR), a protein derived from cleavage
and release from the cell membrane-bound urokinase
plasminogen activator receptor (uPAR), positively corre-
late with the activation level of the immune system.
Numerous observational studies have shown systemic
levels of suPAR to be increased with cancer [1, 2], and
various infectious and inflammatory diseases, including
infections with human immunodeficiency virus (HIV) [3],
malaria [4, 5], tuberculosis [6, 7], central nervous system
infections [8], arthritis [9, 10], liver fibrosis [11], and
inflammatory bowel disease [12]. In addition, systemic
levels of suPAR have been shown to have prognostic
value in predicting the severity and outcome in patients
with cancer [13, 14]. Systemic levels of suPAR were also
found to have a strong prognostic value in HIV-infected
individuals [15, 16].
Systemic levels of suPAR are also increased in criti-
cally ill patients [17]. However, the usefulness of suPAR
as a biological marker in critical illness is uncertain. The
aim of this systematic review is to provide an overview of
studies investigating the diagnostic and prognostic prop-
erties of suPAR in critically ill patients with sepsis,
systemic inflammatory response syndrome, or bacteremia.
We hypothesized that suPAR has both diagnostic and
prognostic value in these inflammatory conditions. We
also hypothesized that systemic concentrations of suPAR
correlate with severity-of-disease classification system
scores and other biological markers of severity of disease.
Finally, we were interested in changes in systemic levels
of suPAR after initiation of treatment to see whether
suPAR has any potential for use in guiding therapy.
Materials and methods
Data sources
Two methods were used to identify relevant papers on
suPAR as a biological marker in critically ill patients in the
medical literature. First, an electronic search in the PubMed
database was performed. Searches were also performed
using the Cochrane Library and the Cochrane Database of
Systematic reviews. Second, reference lists of identified
and selected papers were reviewed for studies not identified
with our search. Searches were restricted to original studies
in humans and manuscripts written in English.
Keywords (text word)
The following keywords were used, alone or in combi-
nation, to identity relevant papers: (1) condition (‘‘critical
care’’ or ‘‘intensive care’’), (2) subject (‘‘human’’), (3) test
(‘‘suPAR’’ or ‘‘soluble urokinase plasminogen activator
receptor’’ or ‘‘soluble uPAR’’ or ‘‘soluble uPA receptor’’
or ‘‘soluble urokinase PA receptor’’ or ‘‘cleaved urokinase
plasminogen activator receptor’’ or ‘‘cleaved uPAR’’ or
‘‘cleaved uPA receptor’’ or ‘‘cleaved urokinase PA
receptor’’ or ‘‘cleaved CD87’’ or ‘‘soluble CD87’’), and
(4) disease (‘‘systemic inflammation,’’ ‘‘SIRS,’’ ‘‘bacter-
emia,’’ ‘‘sepsis,’’ or ‘‘septic shock’’).
Study selection
Titles and abstracts were reviewed, and papers that
reported on studies of suPAR in critically ill patients with
systemic inflammation or infection were selected. Thus,
only papers on studies of critically ill patients were
included (i.e., studies of patients who were admitted to an
intensive care unit or to a hospital with systemic inflam-
mation or infection). In case of uncertainty the complete
paper was obtained and evaluated. Inclusion of papers
was not restricted by methodological quality or any other
critically appraisal criteria other than the criteria formu-
lated for data extraction.
Quality assessment
The quality of the included studies was evaluated by
applying the 25-item criteria developed by the Standards
for Reporting of Diagnostic Accuracy (STARD) com-
mittee [18, 19]. The maximum quality score that could be
given to a study was 25 points over five categories. For
each category, results were derived from consensus
among three reviewers (Y.B, K.S and A.K).
Data extraction
Manuscripts were criticized along the following four
subjects: (1) is suPAR a useful diagnostic marker in
detection of infection, (2) is suPAR a useful prognostic
marker in patients with SIRS, bacteremia or sepsis, (3) do
systemic concentrations of suPAR correlate with disease
severity scores and markers of organ failure in these
patients, and (4) how do systemic levels of suPAR
respond to initiation of treatment?
Results
Search results
The search performed in May 2011 in the PubMed data-
base revealed nine papers as original studies [17, 20–27].
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One additional paper was found in the reference list of
identified and selected papers [28]. The Cochrane Library
and the Cochrane Database of Systematic reviews
revealed no reviews or meta-analyses of suPAR in criti-
cally ill patients. Quality evaluation of the included
studies using the STARD checklist is presented in
Table 1. For 181 of the in total 250 items, complete
agreement was observed between reviewers.
Study populations in the retrieved studies comprised
patients with sepsis and/or septic shock, SIRS and bac-
teremia. Importantly, definitions for diagnoses varied
among the studies. Table 2 presents the criteria used for
diagnosis of each study. Of note, two studies by Kofoed
et al. [22, 23] used the same cohort and data set to
investigate either the diagnostic [22] or the prognostic
[23] value of suPAR.
Seven studies evaluated the diagnostic value of suPAR
[17, 22, 24–28]; six studies investigated the prognostic
value of suPAR [20, 21, 23, 25–27]. Three studies cor-
related systemic levels of suPAR to disease severity
scores [25, 27, 28]; three studies investigated changes of
systemic levels of suPAR after initiation of treatment [25,
27, 28].
In addition, the authors of two publications [25, 26]
kindly provided their raw data, which were used for re-
drawing figures.
Diagnostic value of suPAR
Systemic levels of suPAR were significantly higher in
critically ill patients, compared to healthy controls [17,
24–26, 28]. A gradual increase in levels of suPAR was
seen from critically ill patients who did not fulfill SIRS
criteria to patients with SIRS and patients with sepsis
(Fig. 1) [25]. However, the area under the receiver-
operating characteristic curve (AUC) for suPAR to dis-
criminate between non-septic and septic ICU patients is
reported to be poor (Fig. 2) [25].
Systemic levels of suPAR were significantly higher in
patients with blood culture-positive bacteremia compared
to healthy controls [26]. Levels of suPAR in patients with
gram-positive bacteremia did not appear to be different
from those with gram-negative bacteremia [27]. Also,
suPAR seemed to have no value in discriminating patients
with bacterial infection from patients with viral or para-
sitic infections [22]. Finally, levels of suPAR have been
shown to be similar in patients with pulmonary sepsis and
in those with extra-pulmonary sepsis [25].
Compared to other frequently used biological markers
that can be measured easily with commercially available
kits, including C-reactive protein (CRP), procalcitonin
(PCT), and soluble triggering receptor expressed on
myeloid cells-1 (sTREM-1), suPAR added little to the
diagnostic process [22, 25].
Prognostic value of suPAR
Systemic levels of suPAR were significantly higher in
critically ill patients with fatal outcomes compared to
patients who survive critical illness [20, 21, 23, 25–27].
Although systemic levels of suPAR were consistently
higher in non-survivors on admission as well as on day 3
and 7, the AUC for suPAR to predict ICU mortality in
general ICU patients remained moderate (Fig. 3) [25].
Similar findings were seen in patients with sepsis (Fig. 4)
[25]. In patients who fulfilled at least two criteria for
SIRS, an AUC of 0.80 (cutoff value 6.61 lg/l, sensitivity
89 %, specificity 63 %) for short-term mortality and an
AUC of 0.69 (cutoff value 6.61 lg/l, sensitivity 89 %,
specificity 63 %) for long-term mortality was found [23].
Of note, 64 % of these patients suffered from bacterial
infection, and 15 % had positive blood cultures. In
addition, the AUC in patients with positive blood cultures
was 0.75 (cutoff value 9.25 ng/ml, sensitivity 79 %,
specificity 68 %) for 1-month mortality and AUCs of 0.80
(cutoff value 8.3 ng/ml, sensitivity 71 %, specificity
Table 1 Quality evaluation of the included studies using the Standard for Reporting of Diagnostic Accuracy (STARD) checklist [18, 19]
Study References Years Title/abstract/keywords Introduction Methods Results Discussion Total
Maximum score for each categorya 1 1 11 11 1 25
Mizukami [17] 1995 1 0 6 3 0 10
Molkanen [20] 2011 1 1 8 8 1 19
Moller [21] 2006 1 1 7 6 1 16
Kofoed [22] 2007 1 1 10 8 1 21
Kofoed [23] 2008 1 1 8 7 1 18
Kofoed [24] 2006 0 1 7 3 1 12
Koch [25] 2011 1 1 8 6 1 17
Wittenhagen [26] 2004 1 1 7 5 1 15
Huttunen [27] 2011 1 1 8 8 1 19
Florquin [28] 2001 0 1 6 4 0 11
a For each category, results are derived from consensus among three reviewers as the number of items from the checklist present in the
original article
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78 %) and 0.84 (cutoff value 11 ng/ml, sensitivity 83 %,
specificity 76 %) for hospital mortality [20, 21, 27].
Notably, changes in systemic levels of suPAR over the
first few days in the ICU did not appear to differ between
survivors and non-survivors [25].
As a single biological marker, suPAR was superior in
predicting mortality compared to other frequently used
biological markers, including CRP, PCT and sTREM-1
[20, 21, 23, 25] (Table 3). In addition, the prognostic
performance of suPAR improved when combined with
Table 2 Patients characteristics of the included studies
Study References Criteria used for diagnosis Diagnosis on admission
as described by the
authors (no. of patients)
Type of test used
Mizukami [17] A recognized source of infection or a
hemodynamic profile suggestive of
sepsis, along with fever, granulocytosis,





Molkanen [20] Blood culture positive for S. aureus Bacteremia (59) ELISA
Moller [21] Blood culture positive for S. pneumoniae Bacteremia (128)a ELISA
Kofoed [22] At least two SIRS criteriab SIRS (151) Luminex multiplex assay
Kofoed [23] At least two SIRS criteriab SIRS (151) Luminex multiplex assay
and ELISA
Kofoed [24] Blood culture positive for Pneumococcus
pneumonia or E. coli and at least two
SIRS criteria
Bacterial sepsis (10) Luminex multiplex assay
and ELISA
Koch [25] Severe sepsis and septic shock criteriab Severe sepsis and septic
shock (197)
ELISA
Wittenhagen [26] Blood culture positive for S. pneumoniae Bacteremia (141) ELISA




Florquin [28] Acute symptoms of urinary tract infection,
pyuria, urine gram staining with gram-
bacteria, and metabolic or hematologic
signs of systemic infection, including
two of the three indicators: tachycardia,
leukocytosis or fever
Urosepsis ELISA
a A total of 133 patients were included in this study. Data for
suPAR were accessible from 128 of the patients
b Criteria as recommended and defined in the American College of
Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM)
Consensus Conference [29]







n=43 n=273 n=40 n=36 n=197 n=141
ns***
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Fig. 1 Systemic levels of
suPAR in healthy controls and
critically ill patients with SIRS
or sepsis, and patients with
bacteremia. Systemic levels of
suPAR are significantly higher
in patients with sepsis, as
compared to patient without
sepsis or patients with SIRS.
Data represent medians with
their interquartile range.
Extremes were excluded from
the figure. Stars indicate the
level of statistical difference.
Reproduced with permission
from [25] and [26]
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other biological markers or age [23] (Table 3). While the
ability of suPAR to predict mortality was poor compared
to the conventional simplified acute physiology score
(SAPS) II [23, 25], the prognostic performance of SAPS
II improved when combined with suPAR levels [23]
(Table 3).
Levels of suPAR did not seem predictive of length of
ICU stay [25]. High systemic levels of suPAR were
associated with the need for ICU admission, and need for
vasopressors and mechanical ventilation [27].
Correlation between suPAR and organ failure markers
and disease severity scores
In non-septic and septic patients, systemic levels of suPAR
correlated with several markers of organ dysfunction,
including creatinine, urea and cystatin C (kidney), biliru-
bin, gamma glutamyl transpeptidase, alkaline phosphatase
and albumin (liver), and INR and antithrombin (coagula-
tion) [25]. Similar associations were described for blood
culture-positive bacteremic patients [27].
In the general ICU population, systemic levels of
suPAR correlated with Acute Physiology and Chronic
Fig. 2 Diagnostic power of suPAR. ROC curve analysis showing
the diagnostic power of systemic levels of suPAR in predicting
sepsis on admission. AUC, area under the curve. The p value
indicates the level of statistical significance. Adapted with permis-
sion from [25]
Fig. 3 Prognostic power of
suPAR in ICU patients. Box
plot graphics and ROC curve
analyses showing the prognostic
power of suPAR for mortality
on admission, and day 3 and 7
after admission in ICU patients.
AUC, area under the curve. The
P–value indicates the level of
statistical significance. Adapted
with permission from [25]
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Health Evaluation (APACHE) II scores, SAPS II, and
Sequential Organ Failure Assessment (SOFA) scores [25].
In patients with sepsis, systemic levels of suPAR also
correlated with APACHE II scores and SAPS II, but not
with SOFA scores [25]. Of note, in patients with urosepsis
no correlation with APACHE II scores was found [28]. In
bacteremic patients, however, high suPAR levels were
associated with high SOFA scores [27].
Systemic levels of suPAR after initiation
of antimicrobial treatment
Three studies evaluated levels of suPAR after the initia-
tion of treatment [25, 27, 28]. Systemic levels of suPAR
remained elevated for hours in patients with urosepsis
[28] and for at least the first week in a general ICU
population [25]. In bacteremic patients, systemic levels of
suPAR tended to decline only after several weeks [27].
Factors that influence levels of suPAR
and/or its performance
Some studies showed that the type of assay used to
measure suPAR as well as age of patients and underlying
diseases affected levels of suPAR and/or its performance.
The types of test used for measurement of suPAR are
decribed in Table 2. In one study the suPARnosticTM
(Virogates, Copenhagen, Denmark) assay was compared
with the Luminex assay in the same cohort of patients and
showed a better prognostic performance (AUC of 0.80 vs.
0.68 in predicting short-term mortality; AUC of 0.69 vs.
0.54 in predicting long-term mortality) [23]. Another
study found a correlation coefficient between suPAR
concentrations obtained with a Luminex (8-plex) assay
and a suPAR ELISA of 0.95 with a 95 % limits of
agreement between 99–140 % [24].
Studies that investigated systemic levels of suPAR in
relation to age are contradictory [20, 21, 25–27]. Two
studies found no correlation between systemic levels of
suPAR and age [25, 26]. However, two other studies
suggested higher levels of suPAR in elderly patients [20,
27], and one study showed lower levels in very old
patients [21]. Of note, in patients with bacteremia with
age C75 years, differences in systemic levels of suPAR
between surviving and non-surviving patients were not
significant [21].
Underlying diseases may affect levels of suPAR. In
patients with bacteremia levels of suPAR were higher in
patients with chronic alcohol abuse or liver disease, while
levels were lower in patients with cancer [26, 27]. Inter-
estingly, after adjusting for possible confounders,
including age and underlying diseases, systemic levels of
suPAR remained independently prognostic for mortality
[20, 25–27].
Discussion
This systematic review shows that although systemic
levels of suPAR are elevated with SIRS, bacteremia, and
sepsis, its diagnostic value is low, as suPAR is a non-
specific marker of inflammation. Systemic levels of
suPAR, however, do have prognostic value, with higher
levels being associated with increased mortality. Systemic
levels of suPAR correlate positively with severity-of-
disease classification scores. Systemic levels of suPAR
also correlate positively with several markers of organ
dysfunction. After initiation of therapy, levels of suPAR
decline only on long-term follow-up.
Ideally, biological markers of sepsis should differen-
tiate among bacterial, viral and fungal infection, and
between systemic sepsis and local infection. Over 150
biological markers have been clinically evaluated for use
in sepsis [30]. Relatively few biological markers, how-
ever, have been used for diagnosing (the type of) sepsis,
and none has sufficient sensitivity or specificity to be used
routinely in daily practice [30]. C-reactive protein and
Fig. 4 Prognostic power of
suPAR in patients with sepsis.
Box plot graphics and ROC
curve analyses showing the
prognostic power of suPAR for
mortality on admission in
patients with sepsis. AUC area
under the curve. The p value




procalcitonin are the most widely used values, despite
their limited ability to distinguish sepsis from other
inflammatory conditions [30]. Our review showed suPAR
to have low diagnostic value in patients with SIRS, bac-
teremia, or sepsis, even lower than CRP, PCT, and
sTREM-1.
The majority of the biological markers investigated in
septic patients have been assessed according to their
prognostic value [30]. Traditional markers such as fever,
white blood cell count, and CRP levels are not reliable for
assessing disease severity and mortality risk [30, 31].
Procalcitonin seems to be an improvement on these
markers, but is not ideal [32–34]. Although PCT has
repeatedly been shown to have prognostic value in criti-
cally ill patients, the value of a single level on admission
is limited [35]. The compiled data in this paper suggest
that suPAR has superior prognostic value compared to
commonly used biological markers, including PCT.
Moreover, in contrast to most other markers, circadian
changes in plasma levels of suPAR are minimal [28, 36].
Measurement is therefore largely independent of the
sampling schedule, improving the potential of suPAR as a
marker in clinical routine.
It has been suggested that suPAR is involved in the
plasminogen-activating pathway, inflammation, and the
modulation of cell adhesion, migration, and proliferation
[37]. Soluble urokinase-type plasminogen activator
receptor derives from proteolytic cleavage and release
from cell membrane-bound urokinase plasminogen acti-
vator receptor (uPAR). Both membrane-bound and soluble
uPARs have been shown to bind to integrins [38, 39], and
have been proposed to be involved in cell adhesion and
Table 3 Prognostic value of suPAR to predict mortality as compared to other biological markers and disease severity scores







General intensive care unit population
ICU mortality suPAR 0.67 (0.54–0.80) – – – [25]
CRP 0.54 (0.40–0.68) – – –
PCT 0.58 (0.46–0.71) – – –
SAPS II 0.83 (0.74–0.91) – – –
APACHE II 0.60 (0.45–0.74) – – –
Long-term mortalitya suPAR 0.67 (0.55–0.78) – – – [25]
CRP 0.55 (0.43–0.67) – – –
PCT 0.62 (0.50–0.74) – – –
SAPS II 0.73 (0.62–0.84) – – –
APACHE II 0.63 (0.51–0.75) – – –
Patients with infectious diseasesb
30-Day mortality suPAR 0.80 (0.69–0.92) 6.61 lg/L 89 63 [23]
sTREM-1 0.69 (0.52–0.86) 9.00 lg/L 100 36
MIF 0.65 (0.46–0.84) 1.27 lg/L 78 54
suPAR ? age 0.92 (0.86–0.97) 3.43 100 78
suPAR ? sTREM–1 ? MIF 0.84 (0.70–0.98) 2.40 67 93
suPAR ? sTREM–1 ? MIF ? age 0.93 (0.88–0.98) 3.40 100 81
SAPS II 0.89 (0.80–0.98) 22.5 100 68
SOFA 0.80 (0.65–0.94) 4.5 44 95
suPAR ? SAPS II 0.93 (0.86–1.00) – – –
180-Day mortality suPAR 0.69 (0.57–0.81) 6.61 lg/L 68 64 [23]
sTREM-1 0.69 (0.58–0.80) 9.00 lg/L 95 38
MIF 0.54 (0.39–0.68) 0.81 lg/L 42 72
suPAR ? age 0.86 (0.79–0.94) 4.62 79 83
suPAR ? sTREM–1 ? MIF 0.72 (0.59–0.84) 1.87 58 83
suPAR ? sTREM–1 ? MIF ? age 0.87 (0.79–0.94) 4.55 79 84
SAPS II 0.91 (0.86–0.96) 22.5 100 73
SOFA 0.75 (0.64–0.86) 1.5 74 61
suPAR ? SAPS II 0.92 (0.87–0.97) – – –
Bacteremic patients
1-Month mortality suPAR 0.75 (0.62–0.89) 9.25 ng/ml 79 68 [20]
CRP 0.60 (0.44–0.75) – – –
Hospital mortality suPAR 0.80 (0.62–0.90) 8.3 ng/mL 71 78 [21]
CRP 0.76 (0.59–0.86) 1360 nmol/L 82 69
APACHE II Acute Physiology and Chronic Health Evaluation II
score, CRP C-reactive protein, MIF macrophage migration inhibi-
tory factor, PCT procalcitonin, SAPS II Simplified Acute
Physiology Score II, SOFA Sequential Organ Failure Assessment,
sTREM-1 soluble triggering receptor expressed on myeloid cells
type 1
a Long-term follow-up period: median 348 days (range 29–884)
b Of these patients, 64 % suffered from bacterial infection, and
15 % had positive blood cultures
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proliferation. The soluble form of uPAR has been reported
to have direct chemotactic properties, which may facilitate
recruitment of inflammatory cells such as neutrophils and
monocytes [40, 41], and the mobilization of hematopoietic
stem cells [42]. In addition to its role in adhesion and
migration, suPAR has recently been shown to inhibit
neutrophil efferocytosis [43], while the membrane-bound
form of uPAR has been shown to facilitate phagocytosis of
bacteria [44]. Impaired engulfment of apoptotic neutro-
phils or bacteria has been associated with poor outcome in
preclinical models of sepsis [44, 45]. Cleavage of uPAR
may therefore reflect a functional impairment of the host
defense rather than a surrogate marker of inflammation,
which might explain the higher prognostic value of suPAR
compared to other biological markers.
Although suPAR alone did not perform as well as the
SAPS II score, this does not necessarily preclude its use in
prognostication. APACHE II score, SAPS II, SOFA
score, and other scoring systems estimating the risk of
mortality have become increasingly popular in the field of
research with critically ill patients over the last decades.
However, in clinical practice these scoring systems have
important limitations. Data collection requires multiple
laboratory measurements and the computation of multiple
variables, and is labor intensive and expensive [46–48].
Therefore, the application of these scoring systems may
be limited, particularly when health care is subject to
financial constraint. Soluble urokinase-type plasminogen
activator receptor may have other important advantages.
Only one blood sample instead of multiple clinical and
laboratory measurements are needed. Measurement of
suPAR can be performed using a simple ELISA. In
addition, suPAR is stable in plasma samples subjected to
repeated freeze-thaw procedures [49], increasing its
practicality as a practical biological marker. Thus, based
on the findings that systemic levels of suPAR are a strong
and robust marker of mortality risk, one could speculate
that suPAR will eventually serves as a quick, technically
simple and inexpensive alternative to the current sophis-
ticated severity-of-disease classification systems. Future
studies are needed to address this hypothesis.
The usefulness of suPAR in mortality prediction of
individual patients is uncertain. One can hypothesize that
specific therapeutic strategies should be restricted to
patients with a certain level of suPAR as an alternative to
APACHE II or SAPS II scores. Risk stratification and
prediction of outcome can be used for safe decision making
on the need for hospitalization or ICU admission and
identifying patients at low risk suitable for outpatient
management. Thus, suPAR may eventually help to triage
patients. Also, predicted mortalities can be averaged for
groups of patients in order to specify the group’s morbidity.
However, conclusions should be drawn with some caution.
First, patient numbers in studies of suPAR are still very
low. More and larger studies are needed to better define the
prognostic power of suPAR in critically ill patients.
Notably, systemic levels of suPAR remain elevated
long after clinical recovery and only decline after several
weeks. Therefore, the use of suPAR as a biological
marker for guiding therapy is probably limited. However
studies addressing this issue are lacking.
Importantly, the type of assay used to measure suPAR,
as well as age and presence or absence of underlying
diseases all influence suPAR levels. The difference in
prognostic performance between different assays can be
explained by the fact that the Luminex assay uses a
polyclonal detection antibody, whereas the suPARnos-
ticTM assay uses monoclonal antibodies selected because
of their superior clinical value in HIV disease progression
[23]. On the other hand, the Luminex assay has its
advantage in measuring multiple analytes at the same
time [24]. With the prognostic value of suPAR increasing
in combination with other markers, this might compensate
for the slightly impaired performance.
The finding that age as well as underlying disease
influences the systemic level of suPAR is of limited rel-
evance as both age and underlying diseases are known to
increase mortality risk in critically ill patients [50, 51].
Systemic levels of suPAR remained independently prog-
nostic for mortality after adjusting for age and/or
underlying diseases [20, 25–27]. As with other markers
such as CRP and PCT, experience will eventually dictate
the value of suPAR levels in diverse clinical situations.
Of interest, suPAR is not only present in human
plasma or serum, but can also be found in other body
fluids, including urine, cerebrospinal fluid [37], and
pleural, pericardial, and peritoneal fluids [17]. The num-
ber of studies investigating the value of suPAR in body
fluids other than plasma or serum, however, is very lim-
ited. It would be interesting to evaluate the value of local
levels of suPAR in other body fluids, i.e., in bronchoal-
veolar lavage fluid of patients with frequent pulmonary
complications, such as acute lung injury or ventilator-
associated pneumonia.
Finally, this review has limitations. An important
limitation is that not all studies used the ACCP/SCCM
criteria for the diagnosis of bacteremia, SIRS, and sepsis.
Differences in used definitions may hamper interpretation
of the data. However, since the aim of this review is to
describe the value of suPAR in patients with systemic
infection or inflammation and not to compare patients
with SIRS with patients with bacteremia or sepsis, over-
lap between these groups may not hamper interpretation
of the results.
The most common limitation of any systematic review
is publication bias. Unpublished materials were not found
and thus not used. Another limitation is the small number
of studies that could be included. Soluble urokinase-type
plasminogen activator receptor is a relatively new marker,
and the number of publications in critically ill patients is
still low. Also, studies on the prognostic value of suPAR
were very restricted as they focused only on mortality. No
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conclusions can be drawn on the prognostic value of su-
PAR on other clinical outcomes, such as length of ICU
and hospital stay, and duration of mechanical ventilation.
Conclusions
Soluble urokinase-type plasminogen activator receptor
seems a promising prognostic marker in critically ill
patients. Currently, studies are limited to the predictive
potential to estimate the mortality risk in observational
designs. Future studies should demonstrate whether
prognostic assessment translates into better clinical out-
comes and a higher quality of patients care.
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